NR_293_ATI_Pharmacology_Final_Review_2021

NR i293 iATI iPharmacology iFinal iReview_2021 i 1) A inurse iis iassessing ia iclient iwho iis itaking ilevothyroxine. iThe inurse ishould irecognize ithat iwhich iof ithe ifollowing ifindings iis ia imanifestation iof ilevothyroxine ioverdose? a) Insomnia i) Rationale: iLevothyroxine ioverdose iwill iresult iin imanifestations iof ihyperthyroidism, iwhich iinclude iInsomnia, itachycardia, iand ihyperthermia. b) Constipation i) Rationale: iConstipation iis ia imanifestation iof ihypothyroidism iand iindicates ian iinadequate idose iof ilevothyroxine. c) Drowsiness i) Rationale: iDrowsiness iis ia imanifestation iof ihypothyroidism iand iindicates ian iinadequate idose iof ilevothyroxine. d) Hypoactive ideep-tendon ireflexes i) Rationale: iHypoactive ideep-tendon ireflexes iare imanifestations iof ihypothyroidism iand iindicate ian iinadequate idose iof ilevothyroxine. 2) A inurse iis ireviewing ithe imedical irecord iof ia iclient iwho ihas ibeen ion ilevothyroxine ifor iseveral imonths. iWhich iof ithe ifollowing ifindings iindicates ia itherapeutic iresponse ito ithe imedication? a) Decrease iin ilevel iof ithyroxine i(T4) i) Rationale: iIf ithe idose iof ithis imedication ihas ibeen iadequate, ithe inurse ishould isee ian iincrease iin ithe iT4. b) Increase iin iweight i) Rationale: iIf ithe idose iof ithis imedication ihas ibeen iadequate, ithe inurse ishould isee ia idecrease iin iweight, ias ihypothyroidism icauses ia idecrease iin imetabolism iwith iweight igain. c) Increase iin ihr iof isleep iper inight i) Rationale: iIf ithe idose iof ithis imedication ihas ibeen iadequate, ithe inurse ishould isee ia idecrease iin ithe ihr iof isleep iper inight, ias ihypothyroidism icauses isluggishness iwith iincreased ihr iof isleep. d) Decrease iin ilevel iof ithyroid istimulating ihormone i(TSH). i) Rationale: iIn ihypothyroidism, ithe inonfunctioning ithyroid igland iis iunable ito irespond ito ithe iTSH, iand ino iendogenous ithyroid ihormones iare ireleased. iThis iresults iin ian ielevation iof ithe iTSH ilevel ias ithe ianterior ipituitary icontinues ito irelease ithe iTSH ito istimulate ithe ithyroid igland. Administration iof iexogenous ithyroid ihormones, isuch ias ilevothyroxine, iturns ioff ithis ifeedback iloop, iwhich iresults iin ia idecreased ilevel iof iTSH. 3) A inurse iis ireviewing ithe imedication ilist ifor ia iclient iwho ihas ia inew idiagnosis iof itype i2 idiabetes imellitus. iThe inurse ishould irecognize iwhich iof ithe ifollowing imedications ican icause iglucose iintolerance? a) Ranitidine i) Serum icreatinine ilevels b) Guafenesin i) Drowsiness iand idizziness c) Prednisone i) Glucose iintolerance iand ihyperglycemia, ipatient imight irequire iincreased idosage iof ihypoglycemic imed. d) Atorvastatin i) Thyroid ifunction itests.